Totally drug-resistant tuberculosis and adjunct therapies

Journal of Internal Medicine

Volumn 277, Issue 4, 2015, Pages 388-405

  Parida, S K ^a   Axelsson Robertson, R ^a,b   Rao, M V ^a   Singh, N ^c   Master, I ^c   Lutckii, A ^d   Keshavjee, S ^e   Andersson, J ^a   Zumla, A ^f   Maeurer, M J ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c King Dinuzulu Hospital   (South Africa)

^d PEDIATRIC RESEARCH AND CLINICAL CENTER FOR INFECTIOUS DISEASES   (Russian Federation)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adjunct therapies; Drug resistance; Extensively drug resistant; Genotype; Multidrug resistant; Mycobacterium tuberculosis

Indexed keywords

BCG VACCINE; TUBERCULOSTATIC AGENT; NITROIMIDAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE;

DRUG REPOSITIONING; DRUG RESISTANT TUBERCULOSIS; GENE SEQUENCE; GENOME; GENOTYPE; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; REVIEW; VITAMIN SUPPLEMENTATION; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; HEALTH; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MUTATION; PHYSIOLOGY;

DRUG RESISTANCE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENOTYPE; GLOBAL HEALTH; HOST-PATHOGEN INTERACTIONS; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLIDINONES;

EID: 84925369382     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12264     Document Type: Review

References (128)

1. Pyle MM. Relative numbers of resistant tubercle bacilli in sputa of patients before and during treatment with streptomycin. Proc Staff Meet Mayo Clin 1947; 22: 465-73.
2. Crofton J, Mitchison DA. Streptomycin resistance in pulmonary tuberculosis. Br Med J 1948; 2: 1009-15.
3. Medical Research Council (MRC). TREATMENT of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid; a Medical Research Council investigation. Br Med J 1950; 2: 1073-85.
4. Fox W, Wiener A, Mitchison DA, Selkon JB, Sutherland I. The prevalence of drug-resistant tubercle bacilli in untreated patients with pulmonary tuberculosis; a national survey, 1955-56. Tubercle 1957; 38: 71-84.
5. Mitchison DA, Selkon JB. Bacteriological aspects of a survey of the incidence of drug-resistant tubercle bacilli among untreated patients. Tubercle 1957; 38: 85-98.
6. Crofton J. Chemotherapy of pulmonary tuberculosis. Br Med J 1959; 1: 1610-4.
7. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-6.
8. Wright ABG, Barrera L, Boulahbal F et al. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - Worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55: 301-5.
9. Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-80.
10. Migliori GB, Besozzi G, Girardi E et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-6.
11. World health organization (WHO). Global tuberculosis report 2013. WHO Library Cataloguing-in-Publication Data 2013 Global tuberculosis control Geneva, Switzerland: WHO/HTM/TB/2013.11
12. Dalton T, Cegielski P, Akksilp S et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380: 1406-17.
13. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12: E070517.1.
14. Velayati AA, Masjedi MR, Farnia P et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009; 136: 420-5.
15. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54: 579-81.
16. Udwadia Z, Vendoti D. Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining. J Epidemiol Community Health 2013; 67: 471-2.
17. Velayati AA, Farnia P, Ibrahim TA et al. Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy. Chemotherapy 2009; 55: 303-7.
18. Velayati AA, Farnia P, Merza MA et al. New insight into extremely drug-resistant tuberculosis: using atomic force microscopy. Eur Respir J 2010; 36: 1490-3.
19. Farnia P, Mohammad RM, Merza MA et al. Growth and cell-division in extensive (XDR) and extremely drug resistant (XXDR) tuberculosis strains: transmission and atomic force observation. Int J Clin Exp Med 2010; 3: 308-14.
20. Klopper M, Warren RM, Hayes C et al. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis 2013; 19: 449-55.
21. WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB). 2010 Global report on surveillance and response. Geneva: World Health Organization, 2010.
22. Srivastava S, Sherman C, Gumbo T. In vitro susceptibility testing and totally drug-resistant tuberculosis. Eur Respir J 2013; 42: 291-2.
23. Lawn SD, Mwaba P, Bates M et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013; 13: 349-61.
24. Jacobson KR, Theron D, Kendall EA et al. Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis 2013; 56: 503-8.
25. Barnard M, Warren R, Gey Van Pittius N et al. Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. Am J Respir Crit Care Med 2012; 186: 1298-305.
26. Baylan O, Kisa O, Albay A, Doganci L. Evaluation of a new automated, rapid, colorimetric culture system using solid medium for laboratory diagnosis of tuberculosis and determination of anti-tuberculosis drug susceptibility. Int J Tuberc Lung Dis 2004; 8: 772-7.
27. Moore DA, Evans CA, Gilman RH et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355: 1539-50.
28. Pai M, Kalantri S, Pascopella L, Riley LW, Reingold AL. Bacteriophage-based assays for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a meta-analysis. J Infect 2005; 51: 175-87.
29. Migliori GB, Matteelli A, Cirillo D, Pai M. Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current standards and challenges. Can J Infect Dis Med Microbiol 2008; 19: 169-72.
30. Nosova E, Krasnova MA, Galkina K, Makarova MV, Litvinov VI, Moroz AM. Comparing performance of "TB-BIOCHIP", "Xpert MTB/RIF" and "genotype MTBDRplus" assays for fast identification of mutations in the Mycobacterium tuberculosis complex in sputum from TB patients. Mol Biol (Mosk) 2013; 47: 267-74.
31. McGrath M, Gey van Pittius NC, van Helden PD, Warren RM, Warner DF. Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2014; 69: 292-302.
32. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012; 55: 169-77.
33. Grossman RF, Hsueh PR, Gillespie SH, Blasi F. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones. Int J Infect Dis 2014; 18: 14-21.
34. Smith T, Wolff KA, Nguyen L. Molecular biology of drug resistance in Mycobacterium tuberculosis. Curr Top Microbiol Immunol 2013; 374: 53-80.
35. Colijn C, Cohen T, Ganesh A, Murray M. Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy. PLoS One 2011; 6: e18327.
36. Comas I, Gagneux S. A role for systems epidemiology in tuberculosis research. Trends Microbiol 2011; 19: 492-500.
37. Jenkins C, Bacon J, Allnutt J et al. Enhanced heterogeneity of rpoB in Mycobacterium tuberculosis found at low pH. J Antimicrob Chemother 2009; 63: 1118-20.
38. Walter ND, Strong M, Belknap R, Ordway DJ, Daley CL, Chan ED. Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis. Respirology 2012; 17: 772-91.
39. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970; 20: 810-4.
40. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS medicine 2009; 6: e2.
41. Kato-Maeda M, Ho C, Passarelli B et al. Use of whole genome sequencing to determine the microevolution of Mycobacterium tuberculosis during an outbreak. PLoS One 2013; 8: e58235.
42. Merker M, Kohl TA, Roetzer A et al. Whole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patients. PLoS One 2013; 8: e82551.
43. Roetzer A, Diel R, Kohl TA et al. Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study. PLoS Med 2013; 10: e1001387.
44. Zhang H, Li D, Zhao L et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet 2013; 45: 1255-60.
45. Farhat MR, Shapiro BJ, Kieser KJ et al. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet 2013; 45: 1183-9.
46. Pepper DJ, Rebe K, Morroni C, Wilkinson RJ, Meintjes G. Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. PLoS One 2009; 4: e4520.
47. Bottger EC. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 2011; 17: 1128-34.
48. Gagneux S, DeRiemer K, Van T et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006; 103: 2869-73.
49. Portevin D, Gagneux S, Comas I, Young D. Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages. PLoS Pathog 2011; 7: e1001307.
50. European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis 2006; 12: 736-43.
51. Fleischmann RD, Alland D, Eisen JA et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 2002; 184: 5479-90.
52. Lopez B, Aguilar D, Orozco H et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol 2003; 133: 30-7.
53. Comas I, Chakravartti J, Small PM et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010; 42: 498-503.
54. Ford CB, Lin PL, Chase MR et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 2011; 43: 482-6.
55. Ford CB, Shah RR, Maeda MK et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 2013; 45: 784-90.
56. Marais BJ, Victor TC, Hesseling AC et al. Beijing and Haarlem genotypes are overrepresented among children with drug-resistant tuberculosis in the Western Cape Province of South Africa. J Clin Microbiol 2006; 44: 3539-43.
57. Toungoussova OS, Caugant DA, Sandven P, Mariandyshev AO, Bjune G. Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype. FEMS Immunol Med Microbiol 2004; 42: 281-90.
58. Basile JI, Geffner LJ, Romero MM et al. Outbreaks of mycobacterium tuberculosis MDR strains induce high IL-17 T-cell response in patients with MDR tuberculosis that is closely associated with high antigen load. J Infect Dis 2011; 204: 1054-64.
59. Selwyn PA, Hartel D, Lewis VA et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-50.
60. Stevenson CR, Forouhi NG, Roglic G et al. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 2007; 7: 234.
61. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008; 5: e152.
62. Wu VC, Wang CY, Shiao CC et al. Increased risk of active tuberculosis following acute kidney injury: a nationwide, population-based study. PLoS One 2013; 8: e69556.
63. Skrahina A, Hurevich H, Zalutskaya A et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-31.
64. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
65. Vento S, Lanzafame M. Tuberculosis and cancer: a complex and dangerous liaison. Lancet Oncol 2011; 12: 520-2.
66. Stoffels K, Allix-Beguec C, Groenen G et al. From multidrug- to extensively drug-resistant tuberculosis: upward trends as seen from a 15-year nationwide study. PLoS One 2013; 8: e63128.
67. Maurya V, Vijayan VK, Shah A. Smoking and tuberculosis: an association overlooked. Int J Tuberc Lung Dis 2002; 6: 942-51.
68. Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest 2001; 120: 1514-9.
69. Cox HS, Kalon S, Allamuratova S et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One 2007; 2: e1126.
70. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4: e6914.
71. Espinal MA, Laserson K, Camacho M et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5: 887-93.
72. Singh S, Sankar MM, Gopinath K. High rate of extensively drug-resistant tuberculosis in Indian AIDS patients. AIDS 2007; 21: 2345-7.
73. Gurumurthy P, Ramachandran G, Hemanth Kumar AK et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 2004; 48: 4473-5.
74. Mukherjee T, Boshoff H. Nitroimidazoles for the treatment of TB: past, present and future. Future Med Chem 2011; 3: 1427-54.
75. Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol 2009; 2: 215-8.
76. Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3: e466.
77. Gler MT, Skripconoka V, Sanchez-Garavito E et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-60.
78. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-7.
79. Koul A, Vranckx L, Dendouga N et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008; 283: 25273-80.
80. Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-405.
81. Voelker R. MDR-TB has new drug foe after fast-track approval. JAMA 2013; 309: 430.
82. Protopopova M, Hanrahan C, Nikonenko B et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1, 2-ethylenediamines. J Antimicrob Chemother 2005; 56: 968-74.
83. Tahlan K, Wilson R, Kastrinsky DB et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 1797-809.
84. Migliori GB, Sotgiu G, Gandhi NR et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-79.
85. Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 2010; 54: 2840-6.
86. Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 2006; 58: 332-7.
87. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42: 3251-5.
88. Lee M, Lee J, Carroll MW et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-18.
89. Sotgiu G, Centis R, D'Ambrosio L, Spanevello A, Migliori GB. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 2013; 42: 288-90.
90. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y Acad Sci 2011; 1241: 48-70.
91. Alffenaar JW, van der Laan T, Simons S et al. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob Agents Chemother 2011; 55: 1287-9.
92. Balasubramanian V, Solapure S, Iyer H et al. Bactericidal activity and mechanism of action of AZD5847: a novel oxazolidinone for the treatment of tuberculosis. Antimicrob Agents Chemother 2014; 58: 495-502.
93. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discovery 2013; 12: 388-404.
94. Reddy VM, Dubuisson T, Einck L et al. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 2012; 67: 1163-6.
95. Wallis RS, Jakubiec W, Mitton-Fry M et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One 2012; 7: e30479.
96. Pethe K, Bifani P, Jang J et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 2013; 19: 1157-60.
97. Vilaplana C, Montane E, Pinto S et al. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine 2010; 28: 1106-16.
98. Katoch K, Singh P, Adhikari T et al. Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Vaccine 2008; 26: 1228-34.
99. Dlugovitzky D, Stanford C, Stanford J. Immunological basis for the introduction of immunotherapy with Mycobacterium vaccae into the routine treatment of TB. Immunotherapy 2011; 3: 557-68.
100. Skinner MA, Yuan S, Prestidge R, Chuk D, Watson JD, Tan PL. Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect Immun 1997; 65: 4525-30.
101. Prabowo SA, Groschel MI, Schmidt ED et al. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 2013; 202: 95-104.
102. Coler RN, Bertholet S, Pine SO et al. Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis 2013; 207: 1242-52.
103. Aagaard C, Hoang T, Dietrich J et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011; 17: 189-94.
104. Grode L, Ganoza CA, Brohm C, Weiner J III, Eisele B, Kaufmann SH. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 2013; 31: 1340-8.
105. Malowany JI, McCormick S, Santosuosso M et al. Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptide- or protein-loaded counterparts. Mol Ther 2006; 13: 766-75.
106. Singh V, Jain S, Gowthaman U et al. Co-administration of IL-1+IL-6+TNF-alpha with Mycobacterium tuberculosis infected macrophages vaccine induces better protective T cell memory than BCG. PLoS One 2011; 6: e16097.
107. Skrahin A, Ahmed RK, Ferrara G et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2014; 2: 108-22.
108. Martineau AR, Wilkinson RJ, Wilkinson KA et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 2007; 176: 208-13.
109. Coussens AK, Wilkinson RJ, Hanifa Y et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci USA 2012; 109: 15449-54.
110. Martineau AR, Wilkinson KA, Newton SM et al. IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol 2007; 178: 7190-8.
111. Hossein-nezhad A, Holick MF. Optimize dietary intake of vitamin D: an epigenetic perspective. Curr Opin Clin Nutr Metab Care 2012; 15: 567-79.
112. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010; 10: 482-96.
113. Liu PT, Schenk M, Walker VP et al. Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One 2009; 4: e5810.
114. Sonawane A, Santos JC, Mishra BB et al. Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages. Cell Microbiol 2011; 13: 1601-17.
115. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004; 119: 753-66.
116. Yuk JM, Shin DM, Lee HM et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009; 6: 231-43.
117. Wejse C, Gomes VF, Rabna P et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2009; 179: 843-50.
118. Martineau AR, Timms PM, Bothamley GH et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377: 242-50.
119. Vilcheze C, Hartman T, Weinrick B, Jacobs WR Jr. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction. Nat Commun 2013; 4: 1881.
120. Guzman JD, Evangelopoulos D, Gupta A et al. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open 2013; 3: e002672.
121. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 574-6.
122. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR. Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med 2013; 188: 600-7.
123. Tilley LD, Hine OS, Kellogg JA et al. Gene-specific effects of antisense phosphorodiamidate morpholino oligomer-peptide conjugates on Escherichia coli and Salmonella enterica serovar typhimurium in pure culture and in tissue culture. Antimicrob Agents Chemother 2006; 50: 2789-96.
124. Greenberg DE, Marshall-Batty KR, Brinster LR et al. Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. J Infect Dis 2010; 201: 1822-30.
125. Geller BL, Marshall-Batty K, Schnell FJ, McKnight MM, Iversen PL, Greenberg DE. Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo. J Infect Dis 2013; 208: 1553-60.
126. Lai BS, Witola WH, El Bissati K et al. Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections. Proc Natl Acad Sci USA 2012; 109: 14182-7.
127. Ma F, Xu S, Liu X et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-gamma. Nat Immunol 2011; 12: 861-9.
128. Koser CU, Bryant JM, Becq J et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 2013; 369: 290-2.